By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Dynavax Technologies Corporation 

2929 Seventh Street
Suite 100
Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


SEARCH JOBS

Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.

HEPLISAV-B™ - Our Lead Product Candidate

HEPLISAV-B is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response providing improved protection against hepatitis B. The ongoing Phase 3 study is designed to provide a sufficiently-sized safety database for the FDA to complete its review of Dynavax's biologics license application.

SD-101 - Cancer Immunotherapy

We are utilizing our expertise in TLR biology to develop treatments for cancer by focusing the power of the body’s immune response on cancer cells through optimal stimulation of TLR9 signaling. Our lead cancer immunotherapy product candidate, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells (PDC) to antigen-presenting cells. Our approach provides multiple mechanisms for attacking the tumors along with developing immune memory associated with antigens found in the tumor.

Immune-Mediated Diseases

TLR signaling plays an important role in a variety of immune-mediated diseases including asthma and certain autoimmune and inflammatory diseases. Through modulation of TLR signaling we are developing product candidates that can inhibit stimulation of TLRs that lead to autoimmune and inflammatory diseases as well using TLR agonist to rebalance the Th1 versus Th2 response in asthma


Key Statistics


Email: contact@dynavax.com
Ownership: Public

Web Site: Dynavax
Employees:
Symbol: DVAX
 









Company News
10 Major Pharma and FDA Catalysts Coming in December 12/6/2016 6:22:00 AM
Dynavax (DVAX) Presents Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, In Combination With Targeted Low-Dose Radiation, At American Society of Hematology Annual Meeting 12/5/2016 11:21:19 AM
Dynavax (DVAX) To Webcast Cancer R&D Day On December 9, 2016 12/1/2016 8:47:37 AM
Dynavax (DVAX) To Present Clinical Data From Immuno-oncology Product Candidate, SD-101 11/30/2016 10:56:59 AM
Bay Area's Dynavax (DVAX) Plunges After the FDA Spurns HEPLISAV-B Again 11/14/2016 5:36:43 AM
Dynavax (DVAX) Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, At Society For Melanoma Research 11/9/2016 10:18:56 AM
Dynavax (DVAX) Reports Third Quarter 2016 Financial Results And Company Update 11/7/2016 10:02:30 AM
Dynavax (DVAX) Secures Committed Financing From Deerfield For $100 Million Of Senior Secured Notes 10/27/2016 9:02:21 AM
Dynavax (DVAX) Presents Data Showing That HEPLISAV-B Provides Significantly Higher Seroprotection Rates Against Hepatitis B Infection In Populations Known To Have A Reduced Immune Response To Currently Licensed Vaccines 10/26/2016 8:42:47 AM
Bay Area's Dynavax (DVAX) Could Need a Plan B if Heplisav-B is Rejected in December 10/17/2016 6:00:18 AM
12345678910...
//-->